BLCM Insider Trading
BLCM | Market Equity
Comprehensive Trading Performance Summary
The investment history of corporate insiders at BLCM provides a unique lens into the internal conviction of the company's leadership. By analyzing SEC Form 4 filings, investors can track how directors and officers are allocating their own capital. High-conviction buying often signals that management believes the current market price significantly undervalues future growth prospects, while strategic selling might occur for personal liquidity or portfolio diversification. Monitoring these shifts in ownership is essential for understanding the alignment between management and shareholders in the Market Equity sector.
Transactions on Chart
Open Full Chart| Filing Date | Trade Date | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|
| 2020-03-19 19:48 | 2020-03-17 | Fair Richard A. | Director, Officer - President and CEO | BUY | $4.00 | 5,000 | $19,999 | 5,000 | +100.0% |
| 2019-09-12 02:01 | 2019-09-10 | Fair Richard A. | Director, Officer - President and CEO | BUY | $1.25 | 40,000 | $50,000 | 66,561 | +150.6% |
| 2019-08-30 23:01 | 2019-08-29 | Ward Shane | Officer - Sr. VP and General Counsel | BUY | $1.23 | 8,000 | $9,822 | 18,294 | +77.7% |
| 2019-08-23 23:03 | 2019-08-21 | Fair Richard A. | Director, Officer - President and CEO | BUY | $0.99 | 20,000 | $19,780 | 26,561 | +304.8% |
| 2018-11-14 00:01 | 2018-11-09 | Stonehouse Jon P | Director | BUY | $4.56 | 10,000 | $45,600 | 10,000 | +100.0% |
| 2018-09-05 23:02 | 2018-09-04 | Spencer David M. | Officer - Chief Technology Officer | SELL | $7.04 | 10,000 | $70,413 | 89,939 | -10.0% |
| 2018-07-20 23:01 | 2018-07-18 | Spencer David M. | Officer - Chief Technology Officer | SELL | $7.63 | 40,000 | $305,132 | 99,939 | -28.6% |
| 2018-05-29 23:49 | 2018-05-25 | Musso Alan A | Officer - CFO and Treasurer | SELL | $7.97 | 6,206 | $49,466 | 26,548 | -18.9% |
| 2018-01-20 00:57 | 2018-01-17 | BAKER BROS. ADVISORS LP | 10% owner | SELL | $8.20 | 880,735 | $7,219,913 | 58,131 | -93.8% |
| 2018-01-12 00:02 | 2018-01-09 | Smith Alan K. | Officer - EVP, Technical Operations | SELL | $9.40 | 487 | $4,578 | 2,087 | -18.9% |
| 2017-12-14 00:05 | 2017-12-11 | Musso Alan A | Officer - CFO and Treasurer | SELL | $9.33 | 17,117 | $159,667 | 31,585 | -35.1% |
| 2017-11-30 01:06 | 2017-11-27 | Musso Alan A | Officer - CFO and Treasurer | SELL | $9.89 | 6,206 | $61,382 | 48,702 | -11.3% |
| 2017-07-26 23:29 | 2017-07-24 | Smith Alan K. | Officer - EVP, Technical Operations | SELL | $11.85 | 437 | $5,178 | 1,600 | -21.5% |
| 2017-07-17 23:20 | 2017-07-13 | Moseley Ken | Officer - Sr. VP and General Counsel | OPT+S | $12.26 | 13,823 | $169,470 | 491 | 0.0% |
| 2017-07-12 23:43 | 2017-07-10 | Spencer David M. | Officer - Chief Scientific Officer | SELL | $11.54 | 10,000 | $115,400 | 138,965 | -6.7% |
| 2017-05-26 22:07 | 2017-05-25 | Musso Alan A | Officer - CFO and Treasurer | SELL | $12.24 | 6,311 | $77,254 | 54,908 | -10.3% |
| 2017-03-29 00:05 | 2017-03-24 | BAKER BROS. ADVISORS LP | 10% owner | BUY | $12.00 | 166,666 | $1,999,992 | 4,527,089 | +3.8% |
| 2017-02-10 00:11 | 2017-02-07 | Slawin Kevin M. | Director | SELL | $12.54 | 30,000 | $376,215 | 294,982 | -9.2% |
| 2016-12-20 00:13 | 2016-12-15 | Slawin Kevin M. | Director, Officer - Chief Technology Officer | SELL | $15.45 | 30,000 | $463,539 | 324,982 | -8.5% |
| 2016-12-06 02:42 | 2016-12-05 | Spencer David M. | Officer - Chief Scientific Officer | SELL | $20.00 | 5,000 | $100,000 | 146,082 | -3.3% |
| 2016-12-06 00:09 | 2016-12-01 | Spencer David M. | Officer - Chief Scientific Officer | SELL | $17.52 | 5,000 | $87,625 | 151,082 | -3.2% |
| 2016-12-06 00:07 | 2016-12-01 | Moseley Annemarie | Officer - COO/EVP Clinical Development | OPT+S | $17.54 | 25,000 | $438,505 | 442 | 0.0% |
| 2016-11-30 00:05 | 2016-11-25 | Musso Alan A | Officer - CFO and Treasurer | SELL | $19.51 | 29,300 | $571,640 | 60,548 | -32.6% |
| 2016-09-24 01:57 | 2016-09-21 | Spencer David M. | Officer - Chief Scientific Officer | SELL | $19.88 | 16,500 | $328,017 | 156,082 | -9.6% |
| 2016-09-24 01:56 | 2016-09-21 | Slawin Kevin M. | Director, Officer - Chief Technology Officer | SELL | $20.12 | 23,416 | $471,088 | 354,982 | -6.2% |
| 2016-09-24 01:55 | 2016-09-21 | Moseley Ken | Officer - Sr. VP and General Counsel | OPT+S | $20.10 | 11,800 | $237,202 | 344 | 0.0% |
| 2016-09-21 01:21 | 2016-09-16 | Slawin Kevin M. | Director, Officer - Chief Technology Officer | SELL | $20.01 | 4,584 | $91,713 | 367,040 | -1.2% |
| 2016-09-21 01:20 | 2016-09-16 | Spencer David M. | Officer - Chief Scientific Officer | SELL | $20.01 | 2,500 | $50,028 | 172,582 | -1.4% |
| 2016-09-21 01:19 | 2016-09-16 | Moseley Ken | Officer - Sr. VP and General Counsel | OPT+S | $20.01 | 2,200 | $44,018 | 344 | 0.0% |
| 2016-08-17 23:11 | 2016-08-15 | Slawin Kevin M. | Director, Officer - Chief Technology Officer | SELL | $19.31 | 67,000 | $1,293,944 | 368,982 | -15.4% |
| 2016-08-17 23:09 | 2016-08-15 | Spencer David M. | Officer - Chief Scientific Officer | SELL | $20.00 | 1,000 | $20,000 | 175,082 | -0.6% |
| 2016-08-17 23:09 | 2016-08-15 | Moseley Ken | Officer - Sr. VP and General Counsel | OPT+S | $20.00 | 1,000 | $20,000 | 344 | 0.0% |
| 2016-07-30 00:50 | 2016-07-27 | Slawin Kevin M. | Director, Officer - Chief Technology Officer | SELL | $15.00 | 15,000 | $225,000 | 399,982 | -3.6% |
| 2016-07-30 00:48 | 2016-07-27 | Spencer David M. | Officer - Chief Scientific Officer | SELL | $15.00 | 10,000 | $150,000 | 176,082 | -5.4% |
| 2016-07-20 01:42 | 2016-07-18 | Slawin Kevin M. | Director, Officer - Chief Technology Officer | SELL | $13.99 | 2,719 | $38,044 | 134,206 | -2.0% |
| 2016-07-19 23:02 | 2016-07-15 | Slawin Kevin M. | Director, Officer - Chief Technology Officer | SELL | $13.72 | 22,281 | $305,677 | 136,925 | -14.0% |
| 2016-06-06 23:06 | 2016-06-02 | Moseley Annemarie | Officer - COO/EVP Clinical Development | OPT+S | $13.00 | 25,000 | $325,000 | 251 | 0.0% |
| 2016-06-06 23:06 | 2016-06-02 | Moseley Ken | Officer - Sr. VP and General Counsel | OPT+S | $13.00 | 15,000 | $195,000 | 196 | 0.0% |
| 2016-04-26 23:06 | 2016-04-22 | Slawin Kevin M. | Director, Officer - Chief Technology Officer | SELL | $11.43 | 55,000 | $628,496 | 414,982 | -11.7% |
| 2016-01-07 00:20 | 2016-01-04 | Moseley Annemarie | Officer - COO/EVP Clinical Development | OPT+S | $19.07 | 35,000 | $667,496 | 251 | 0.0% |
| 2015-12-04 00:16 | 2015-12-01 | Spencer David M. | Officer - Chief Scientific Officer | SELL | $22.95 | 5,000 | $114,739 | 178,600 | -2.7% |
| 2015-11-28 00:50 | 2015-11-24 | Musso Alan A | Officer - CFO and Treasurer | SELL | $22.34 | 29,300 | $654,459 | 88,742 | -24.8% |
| 2015-11-18 19:44 | 2015-11-16 | Slawin Kevin M. | Director, Officer - Chief Technology Officer | SELL | $20.65 | 24,000 | $495,509 | 398,066 | -5.7% |
| 2015-11-04 21:36 | 2015-11-02 | Moseley Ken | Officer - Sr. VP and General Counsel | OPT+S | $13.00 | 15,000 | $195,000 | 97 | 0.0% |
| 2015-10-06 13:11 | 2015-10-01 | Farrell Thomas J. | Director, Officer - President and CEO | SELL | $14.58 | 2,500 | $36,442 | 63,862 | -3.8% |
| 2015-09-15 23:11 | 2015-09-11 | Spencer David M. | Officer - Chief Scientific Officer | SELL | $19.00 | 5,000 | $95,000 | 178,600 | -2.7% |
| 2015-09-03 23:55 | 2015-09-01 | Farrell Thomas J. | Director, Officer - President and CEO | SELL | $16.78 | 2,500 | $41,943 | 66,362 | -3.6% |
| 2015-08-06 00:07 | 2015-08-03 | Farrell Thomas J. | Director, Officer - President and CEO | SELL | $20.24 | 2,500 | $50,608 | 68,862 | -3.5% |
| 2015-07-17 23:59 | 2015-07-15 | Slawin Kevin M. | Director, Officer - Chief Technology Officer | SELL | $20.00 | 6,000 | $120,000 | 402,066 | -1.5% |
| 2015-07-07 00:00 | 2015-07-01 | Moseley Ken | Officer - Sr. VP and General Counsel | OPT+S | $20.62 | 15,000 | $309,267 | 97 | 0.0% |
How to Interpret $BLCM Trades
Not every insider transaction in BLCM is a signal for immediate action. Professional investors look for "cluster buying"—when multiple executives simultaneously purchase $BLCM shares on the open market. It is crucial to distinguish between scheduled sales (under Rule 10b5-1) and voluntary increases in ownership, which demonstrate management’s true conviction that the stock is undervalued.
Data Source & Accuracy for BLCM
Insider activity data for BLCM is streamed in real-time directly from the SEC EDGAR system. We analyze raw Form 4 filings, filtering out technical adjustments and complex derivative transactions. This provides a transparent view of how ownership structure is evolving in $BLCM, allowing you to follow the capital of those with the most intimate knowledge of the company.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.